News

Featured News:

HCRP: Perspective on Drug Pricing in the US

Where do we expect the current political furor over drug pricing to lead? Drug pricing is one of the populist issues that both Democrats and Republicans are exploiting in the presidential race - it is hard to predict any specific outcome, but certain trends seem likely. read more

THE INFORMATION CONTAINED IN THIS INTERVIEW IS PROVIDED FOR INFORMATIONAL AND DISCUSSION PURPOSES ONLY AND IS NOT, AND MAY NOT BE RELIED ON IN ANY MANNER AS, LEGAL, TAX OR INVESTMENT ADVICE OR AS AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY AN INTEREST IN HEALTHCARE ROYALTY PARTNERS FUNDS (EACH A “FUND“ AND TOGETHER WITH ITS AFFILIATES "HEALTHCARE ROYALTY PARTNERS"). A PRIVATE OFFERING OF INTERESTS IN THE FUND WILL ONLY BE MADE PURSUANT TO A CONFIDENTIAL PRIVATE PLACEMENT MEMORANDUM (AN “OFFERING MEMORANDUM“) AND THE FUND’S SUBSCRIPTION DOCUMENTS, WHICH WILL BE FURNISHED TO QUALIFIED INVESTORS ON A CONFIDENTIAL BASIS AT THEIR REQUEST FOR THEIR CONSIDERATION IN CONNECTION WITH SUCH OFFERING. THE INFORMATION CONTAINED HEREIN IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO THE OFFERING MEMORANDUM OF EACH FUND, WHICH CONTAIN ADDITIONAL INFORMATION ABOUT THE INVESTMENT OBJECTIVES, TERMS AND CONDITIONS OF AN INVESTMENT IN THE FUND AND ALSO CONTAINS TAX INFORMATION AND RISK DISCLOSURES THAT ARE IMPORTANT TO ANY INVESTMENT DECISION REGARDING A FUND. NO PERSON HAS BEEN AUTHORIZED TO MAKE ANY STATEMENT CONCERNING THE FUND OTHER THAN AS SET FORTH IN THE OFFERING MEMORANDUM AND ANY SUCH STATEMENTS, IF MADE, MAY NOT BE RELIED UPON.

IN CONSIDERING ANY PERFORMANCE DISCUSSED IN THIS INTERVIEW, INVESTORS SHOULD BEAR IN MIND THAT PAST, PROJECTED, OR TARGETED PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS, AND THERE CAN BE NO ASSURANCE THAT ANY INVESTMENT WILL ACHIEVE COMPARABLE RESULTS. CERTAIN OF THE FACTUAL STATEMENTS MADE IN THIS INTERVIEW ARE BASED UPON INFORMATION FROM VARIOUS SOURCES BELIEVED BY HEALTHCARE ROYALTY PARTNERS TO BE RELIABLE. HEALTHCARE ROYALTY PARTNERS AND THE FUND HAVE NOT INDEPENDENTLY VERIFIED ANY OF SUCH INFORMATION AND SHALL HAVE NO LIABILITY ASSOCIATED WITH THE INACCURACY OR INADEQUACY THEREOF.

Press Releases

In the News

Feb 03 2017 Portola Pharmaceuticals Signs $150 Million Royalty Agreement with HCR
Jan 27 2017 Healthcare Royalty Partners Announces New Chief Medical Officer, Senior-Level Promotions, and Further Regional Expansion
Dec 21 2016 XOMA Announces up to $22 Million Generated from Sale of Royalty Streams from Two License Agreements to HealthCare Royalty Partners and Provides Corporate Update
Dec 12 2016 Grünenthal to acquire commercialization rights of Qutenza® in Europe from Astellas Pharma Europe
Nov 07 2016 Progenics Announces $50 Million RELISTOR® Royalty-Backed Financing
Sep 29 2016 Stereotaxis Completes Private Placement of $24 Million
Sep 12 2016 Horizon Pharma to Acquire Raptor Pharmaceuticals
Sep 09 2016 AcuFocus Raises $66 Million in New Financing Round Led by KKR
Jul 21 2016 Galenica and Relypsa Announce Agreement for Galenica to Acquire Relypsa
Jun 14 2016 Suneva Medical Closes $25 Million Financing to Support Continued Growth Opportunities
May 03 2016 Relypsa Announces $150 Million Debt Financing
Apr 25 2016 Aviragen Completes $20 Million Royalty Financing
Feb 29 2016 Coherus Announces $100 Million Private Placement
Oct 19 2015 HealthCare Royalty Partners Strengthens Investment Team
Jun 01 2015 HCRP Strengthens Team and Expands to West Coast
Apr 17 2015 AcuFocus Wins FDA Approval for The KAMRA™ Inlay
Jan 06 2015
Suneva's Bellafill Receives FDA Approval for Acne Scars
Dec 10 2014 Former Janney Investment Banking Head Chris White Appointed COO
Oct 20 2014 HC Royalty Raises $1.5 Billion
Sep 17 2014 Cardiorentis Announces €45 Million Financing
Sep 03 2014 HC Royalty Announces Follow-on Investment in AcuFocus
Jul 08 2014 Supernus to Receive $30 Million in Non-Dilutive Royalty Deal
Jul 01 2014 Raptor Pharmaceutical Enters into $70 Million Financing Transaction and Amended Loan Agreement with HealthCare Royalty Partners
Mar 04 2014 HC Royalty Accelerates Invuity’s Commercialization Efforts with New Financing
Jan 09 2014 Suneva Medical Raises $35 Million in Funding
Dec 04 2013 HealthCare Royalty Partners Appoints Pfizer Veteran to Strategic Advisory Board
Jun 27 2013 HealthCare Royalty Partners Promotes Matthew Reber to Managing Director
Apr 30 2013 Raptor Pharmaceutical's PROCYSBI™ Receives FDA Approval for the Treatment of Nephropathic Cystinosis
Apr 29 2013 Clarke Futch to Speak on BioWorld Webinar
Feb 28 2013 TearScience® Secures up to $70 Million in Funding from Healthcare Royalty Partners
Jan 04 2013 HC Royalty Expands Strategic Advisory Board
Jan 03 2013 HC Royalty Commits Over $425 Million in 2012
Dec 20 2012 HC Royalty Invests $50 Million in PROCYSBI™
Jun 25 2012 Cowen Royalty Announces Name Change, Unveils New Website
Jun 07 2012 Medigene Monetizes Eligard® Royalty for USD 17.68 Million
May 21 2012 Suneva Medical Acquires Product Portfolio from Spear Pharmaceuticals
Jan 05 2012 HC Royalty Raises $1 Billion
Jan 04 2012 Dyax Corp. Enters into New Loan Agreement with HC Royalty
Dec 01 2011 Stereotaxis Enters $20 Million Royalty Financing Agreement
Nov 29 2011 AcuFocus Raises $65 Million In Funding
Jun 30 2011 Zogenix Enters $30 Million Royalty Financing Agreement With HC Royalty
Feb 28 2011 Aeterna Zentaris Receives $2.5 Million Milestone Payment From HC Royalty
Apr 30 2010 NeurogesX Enters $40 Million Royalty Financing Agreement with HC Royalty
Nov 06 2009 Surviving Healthcare Reform: How Biopharma Companies Can Come Out on Top
Sep 17 2009 HC Royalty Establishes Strategic Advisory Board
Mar 18 2009 Dyax Amends Loan Agreement with HC Royalty for an Additional $15 Million
Nov 12 2008 Æterna Zentaris Agrees to Sell Cetrotide® Royalty Stream for $52.5MM to HC Royalty
Aug 21 2008 LifeCycle Pharma Sells Fenoglide™ Royalty Stream to HC Royalty
Aug 06 2008 Dyax Enters into $50MM Agreement with HC Royalty
Jul 21 2008 HC Royalty Announces Closing of Fund
Feb 22 2017 Smaller finance firms rise to fill gaps in Stamford
Aug 2016 Dealmaking in 2016: It's Complicated
Pharmaceutical Executive Magazine
Apr 10 2016 In Focus: As Lyrica profits dry up, Northwestern seeks another 'blockbuster' drug
The Daily Northwestern
Jun 2015 Hard Science, High Hopes
Pharmaceutical Executive Magazine
Jun 03 2015 PE Wending Its Way Through the ACA
Privcap
May 22 2015 Advisers Find Yield in Medical Royalties
WSJ.com "Wealth Adviser"
Mar 09 2015 Drug Royalty Funds Expand Into Credit Deals
WSJ.com "Private Equity Beat"
Jan 13 2015 "Speed Dating" for Health-Care Deals at J.P. Morgan Conference
WSJ.com "Private Equity Beat"
Oct 20 2014 HealthCare Royalty Partners Closes Third Fund
WSJ.com "Private Equity Beat"
Mar 2014 Maximizing the Value of License Agreements
les Nouvelles
Jan 17 2014 Drugmakers see innovation justifying further price rises
Reuters
Oct 22 2013 Implications of the Affordable Care Act on Life Sciences Dealmaking
LES Insights
Mar 05 2013 For TearScience, Royalty Financing Offered a New Investor Option
Fierce Medical Devices
Mar 01 2013 TearScience Secures $70 million for One-of-a-Kind Eye Device
START-UP
Feb 26 2013 TearScience Raises Up to $70MM in Royalty Debt Financing
WSJ.com
Dec 20 2012 Raptor lines up $50 million loan ahead of decision date on rare disease drug
San Francisco Business Times
Jul 02 2012 Healthcare reform doles out opps for PE, more consolidation
TheDeal.com
Jan 17 2012 Record Year for Royalty Deals
BioWorld
Jan 09 2012 Treated Like Royalty
BioCentury
Jan 05 2012 $1 billion for 'synthetic' pharma royalties
Fortune.com
Nov 29 2011 Med-Tech Start-Ups Using Revenue To Gain Funding
WSJ.com
Jul 01 2011 Seeing the Fire Behind the Smoke
Pharmaceutical Executive
Jun 01 2011 2011 Dealmakers Outlook
Pharmaceutical Executive
Apr 18 2011 HC Royalty Discusses the Biotech Financing Market on CNBC’s The Strategy Session
CNBC
Sep 07 2010 The New Normal
TheDeal.com
May 10 2010 Clarke Futch Named One of the Future Leaders in Biotech
BioWorld 
Sep 30 2009 Royalty Deals Aren’t Just For Start-Ups Anymore
WSJ.com
Sep 09 2009 Experimental Treatment
Institutional Investor
Aug 20 2008 Drug Royalty Financing Thrives In Difficult Market 
Reuters